Quick Answer
Ingevity Corp reported Research And Development Expense of $28.40 million for the year ending 2025.
- Ingevity Corp showed an increase of +15.9% in Research And Development Expense from 2024 to 2025.
- This data is from Ingevity Corp's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2016: $4.60 million | Q2 2016: $4.60 million | Q3 2016: $3.90 million | Q1 2017: $5.10 million | Q2 2017: $4.70 million | Q3 2017: $4.80 million | Q1 2018: $5.00 million | Q2 2018: $5.30 million | Q3 2018: $5.60 million | Q1 2019: $5.10 million | Q2 2019: $5.00 million | Q3 2019: $4.90 million | Q1 2020: $6.20 million | Q2 2020: $5.40 million | Q3 2020: $5.20 million | Q1 2021: $6.60 million | Q2 2021: $5.90 million | Q3 2021: $6.80 million | Q1 2022: $7.30 million | Q2 2022: $8.20 million | Q3 2022: $7.60 million | Q1 2023: $8.80 million | Q2 2023: $8.00 million | Q3 2023: $7.80 million | Q1 2024: $6.80 million | Q2 2024: $7.30 million | Q3 2024: $6.20 million | Q1 2025: $7.70 million | Q2 2025: $7.80 million | Q3 2025: $7.00 million.
- Over the full 11 years of available data (2015 to 2025), Ingevity Corp's Research And Development Expense has grown by 63.2%.
- Historical annual values: Fiscal year 2025: $28.40 million | Fiscal year 2024: $24.50 million | Fiscal year 2023: $25.40 million | Fiscal year 2022: $30.30 million | Fiscal year 2021: $26.30 million | Fiscal year 2020: $22.60 million | Fiscal year 2019: $19.70 million | Fiscal year 2018: $21.50 million | Fiscal year 2017: $19.80 million | Fiscal year 2016: $17.60 million | Fiscal year 2015: $17.40 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: